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Abstract 
Dyskeratosis congenita and its variants have overlapping phenotypes with many 
disorders including Coats plus, and their underlying pathology is thought to be one of 
defective telomere maintenance. Recently biallelic CTC1 mutations have been 
described in patients with syndromes overlapping Coats plus. CTC1, STN1 and 
TEN1 are part of the telomere-capping complex involved in maintaining telomeric 
structural integrity. Based on phenotypic overlap we screened 73 genetically 
uncharacterized patients with dyskeratosis congenita and related bone marrow 
failure syndromes for mutations in this complex. Biallelic CTC1 mutations were 
identified in six patients but none in either STN1 or TEN1. We have expanded the 
phenotypic spectrum associated with CTC1 mutations and report that intracranial 
and retinal abnormalities are not a defining feature as well as showing the effect of 
these mutations on telomere length is variable. The study also demonstrates the lack 
of disease causing mutations in other components of the telomere-capping complex.  
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INTRODUCTION 
Telomeres are nucleoprotein complexes required by the chromosome for stability. 
They protect the chromosome terminus from inappropriate nuclease and repair 
activities, and provide a mechanism to compensate for the inability of DNA 
polymerase to completely replicate the 5’end of the linear chromosome1. Protection 
of the telomere ends in vertebrates and yeast is broadly similar. Both possess a 
nucleoprotein cap that is comprised of double stranded DNA (dsDNA) with a single 
stranded DNA (ssDNA) overhang bound by dsDNA and ssDNA-binding proteins. In 
vertebrates the shelterin complex (comprising TRF1, TRF2, TIN2, RAP1, TPP1 and 
POT1) protects telomeres from degradation. In budding yeast, although the double 
stranded region of the telomere is bound by Rap1 and two other associated proteins; 
these are not involved in telomere protection2. This function is provided by the CST 
complex comprising Cdc13, Stn1 and Ten1 which interact with the single stranded 3’ 
overhang3. Due to the lack of identity with the shelterin complex it was thought these 
were two distinct pathways that had evolved to perform a similar function in different 
organisms.4 Mammalian homologues of the CST complex5,6 have now been 
identified which are CTC1 (conserved telomere maintenance component 1, which is 
similar to Cdc13), human STN1 (originally identified as OB-fold-containing 1 
[OBFC1]) and TEN1. It is now thought that both the CST and shelterin complexes 
have a role in protecting telomeric DNA against inappropriate repair mechanisms 
and recombination7, but their modes of action are different. CTC1 specifically has 
role in promoting efficient DNA replication and maintaining telomere length8. 
Two recent studies have identified mutations in the CTC1 component of the CST 
complex in patients with cerebroretinal microangiopathy with calcifications and cysts 
(CRMCC). This rare multisystem disorder is thought to encompass both Coats plus 
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and leukoencephalopathy with calcifications and cysts (LCC) 9, 10. The key 
characteristics of this disorder include intracranial calcifications and 
leukoencephalopathy, retinal vasculature abnormalities, skeletal abnormalities and 
recurrent gastrointestinal haemorrhage. Dystrophic nails, sparse hair and abnormal 
skin pigmentation have occasionally been observed in such patients11-13. 
Dyskeratosis congenita (DC) is a complex bone marrow failure syndrome in which 
the principal pathology is defective telomere maintenance and it is often associated 
with short telomeres. The classical clinical manifestations include abnormal skin 
pigmentation, nail dystrophy, oral leukoplakia and bone marrow failure14. Seven of 
the genes mutated in DC are associated with either the telomerase holoenzyme 
(TERT, TERC, DKC1, NOP10, NHP2, and TCAB1) or the shelterin complex 
(TINF2)15, accounting for approximately 50% of DC patients. Phenotypically severe 
variants of DC have been identified, known as Hoyeraal-Hreidarsson (HH) and 
Revesz syndromes (RS), and share an overlapping genetic basis. In addition to short 
telomeres, similar genetics and many common clinical features, both can have 
cerebral abnormalities and, in the case of RS, present with retinopathy and 
intracranial calcifications. In light of the clinical overlap between CRMCC (Coats plus 
and LCC) and DC (particularly in the severe variants) the aim of this study was to 
determine whether any of our patients with uncharacterized DC and related 
syndromes had mutations within the CST complex.  
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DESIGN AND METHODS 
Patients 
Patient samples analysed in this study were selected from the collection of bone 
marrow failure samples that comprised in part the dyskeratosis congenita registry 
(DCR) located at Barts and The London. All samples were obtained with informed 
consent and with the approval of our local ethics committee. 73 patients were 
selected for analysis, 55 of whom were registered on the DCR (with sufficient 
features to be classified as DC14). The remaining 18 had features overlapping with 
DC, specifically the HH phenotype but not enough to be entered into the registry, or 
had bone marrow failure and retinal abnormalities. 8/73 patients had either 
retinopathy, Coats plus or RS. All patients had been previously screened for 
mutations in the commonly occurring DC-associated genes. 
 
Gene screening for the CST complex 
Primers (available on request) were designed to amplify the entire coding region of 
CTC1 (NM_025099.5), STN1 (NM_024928.4) and TEN1 (NM_001113324.2). PCR 
products for each exon were pooled pair-wise and analysed by denaturing high 
performance liquid chromatography (dHPLC) using the Transgenomic Wave DNA 
fragment analysis system. All abnormal elution patterns were re-amplified and 
confirmed by direct sequencing using ABI BigDye v3.1 to identify which specific DNA 
harboured the mutation of interest.  
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Telomere length measurement using monochrome multiplex quantitative PCR 
(MM-qPCR)  
Telomere lengths were measured using a multiplex real time PCR method16. Poor 
quality DNAs as assessed by gel electrophoresis were excluded from analysis. All 
samples were measured in triplicate as previously described17. 
 
RESULTS AND DISCUSSION 
Identification of mutations in CTC1 
Compound heterozygous mutations in CTC1 were observed in six patients, (three of 
them fulfilling the diagnostic criteria for DC14, Table 1), resulting in the identification 
of nine heterozygous mutations. Four of these mutations are novel and predicted to 
be probably damaging by PolyPhen2 analysis18 (c.1389_1390insGTTAGGA, 
p.Leu464Valfs*66; c.740T>C, p.Leu247Pro; c.833G>T, p.Gly278Val and c.1270T>G, 
p.Cys424Gly).  Full or partial segregation was only possible in two out of the five 
families due to sample availability; this enabled us to confirm the genotype of a 
second affected sibling in Family 4 as well as demonstrating an autosomal recessive 
pattern of inheritance (Figure 1A). The patient in family 5 (F5: II-3) has been 
previously reported9 but this was only determined after screening as he was an 
uncharacterized case of DC in our registry. No mutations were identified in STN1 or 
TEN1 in this analysis. 
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Clinical presentation 
Mutations in CTC1 are usually described in the context of CRMCC either with or 
without Coats retinopathy9, 10, but more recently one patient presenting with DC has 
been reported19. Two patients (F1: II-1 and F2: II-1) in this study lacked retinopathy, 
whereas F2: II-1 and F5: II-3 had no reported brain abnormalities. These 
observations show that although most patients with CTC1 mutations usually have 
retinal abnormalities and intracranial calcifications there is a subset lacking either or 
both of these features (Table 1). These finding suggest biallelic CTC1 mutations 
produce a spectrum of phenotypes which could come under the heading of “CTC1-
related diseases” rather than CRMCC or Coats retinopathy. 
It is interesting that the only overlap between combinations of mutations seen in our 
patients and those previously reported is patient F2: II-1 and the DC patient seen by 
Keller et al19 for the mutations p.Lys242Leufs*41 and p.Cys985del. Although both 
patients present with DC, the patient in this study does not have retinal disease or 
intracranial calcifications. This suggests other factors affect the phenotype in addition 
to the CTC1 status.  
Reviewing all the literature detailing biallelic CTC1 mutations, genetic analysis has 
been performed on 125 patients. Twenty five different mutations have been identified 
in 30 patients from 26 families. Clustering of these mutations appears to be occurring 
between amino acids 227-287 (7 mutations) and 944-987 (5 mutations, Figure 1B). 
Twenty six patients present with the CRMCC spectrum of disease whereas four 
present with a DC phenotype. One individual has been classified as both CRMCC 
disease spectrum and DC on the basis of its clinical presentation, whereas another 
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with late onset intracranial calcification and retinopathy amongst other characteristics 
has been diagnosed as DC but could be viewed as a Coats plus variant. This 
emphasizes the degree of overlap between the two groups and highlights the 
difficulty of making an accurate clinical diagnosis20.  The degree of retinopathy in 
patients with DC is different in our group compared with previously published 
accounts. Retinal changes were noted in 4/55 DC patients screened (7.4%) 
compared with 21% observed by Tsilou et al21. Overall, in all the previous reports of 
CTC1 mutations, all patients except one had retinal abnormalities. In our study 
group, 8/73 patients had retinal abnormalities whereas only 3 patients with retinal 
abnormalities were found to have CTC1 mutations. In our screen of 55 DC patients, 
mutations in CTC1 are seen in less than 6% of this group. Overall these data 
suggest that any patient who presents with intracranial abnormalities either with or 
without retinal abnormalities should be screened for CTC1 mutations regardless of 
their actual clinical diagnosis. 
 
Telomere lengths are not significantly reduced in patients with biallelic CTC1 
mutations 
Due to the recognized association of short telomeres in patients with DC/HH, and the 
disagreement between telomere lengths observed in CRMCC patients associated 
with CTC1 mutations in the two main studies in the literature9, 10, we measured 
telomere length using a quantitative PCR based method. Telomere lengths were 
measured in the six patients and three parents with CTC1 mutations as well as 143 
controls. T/S ratios from 33 patients with known TERC mutations are included as 
examples of short telomeres (Figure 2A). In this study, there was no significant 
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difference in the T/S ratios between patients and controls. In the three published 
reports, two different methods have been used to measure telomere lengths with 
contradictory results. Anderson et al9 and Keller et al19 used flow-FISH and showed 
that telomeres are below the 1st centile which is considered by some to be diagnostic 
of DC22. Polvi et al used a qPCR based method, and showed there was no 
difference in telomere length in patients with CTC1 mutations compared to controls; 
agreeing with our observations. The difference observed may be due in part to the 
different methods used23, but qPCR is an ideal method to use with archived samples 
with limited DNA quantity.  From previous work we had telomere length data for F2: 
II-1 and F3: II-1 measured by Southern blotting using a pTelBam8 probe and again 
these two individuals did not have short telomeres compared with 124 controls or 24 
patients with known TERC mutations (Figure 2B). F2: II-1 is the DC patient who has 
the identical mutations as the DC patient reported by Keller et al19 but the telomere 
lengths are within the normal range in our patient. This observation by a second 
method suggests that short telomeres are not a hallmark of patients with biallelic 
CTC1 mutations. This is in contrast to the short telomeres which are observed by 
both methods in patients with heterozygous TERC mutations. 
 
Functionally the effects of CTC1 mutations are not well understood. It has been 
shown that in a conditional knockout mouse model a null is initially viable and 
pathogenic features appear with age8. Ctc-/- mice have severe bone marrow failure 
just before death with a complete absence of trilineage haematopoiesis. This could 
account for the bone marrow failure observed in some patients with CTC1 mutations. 
Its involvement in telomere length regulation is more complex. Gu et al8 suggest that 
CTC1 is involved in restarting stalled replication forks at telomeres thereby 
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promoting efficient and complete replication but it is not involved directly in the 
protection of telomeres from adverse DNA damage response mechanisms. The 
differences seen in the mouse model compared with patients is that in the mouse the 
mutation is effectively homozygous and produces a severely truncated product. In 
patients, mutations are only observed as compound heterozygote, which suggest 
that a severe homozygous mutation would be non-viable. Furthermore two truncating 
mutations are not observed in any patient to date suggesting such a combination 
would be non-viable.    
In summary, we have shown in a large series of patients with DC and related bone 
marrow failure syndromes that compound heterozygous CTC1 mutations are a rare 
cause of DC (<6% of uncharacterized DC cases; < 2% of all cases in DCR) and 
related diseases and suggest there is no involvement of the other two members 
(TEN1 and STN1) of the CST complex in this group of diseases. The effect of CTC1 
mutations on telomere length is more variable than has been suggested previously. 
Patient phenotype is also more variable and this report highlights that intracranial 
and retinal abnormalities are not prerequisite features for the presence of mutations 
in CTC1.  
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Table 1. Summary of clinical features and mutation status in affected individuals with compound heterozygous CTC1 mutations. 
 
Family 
Individual 
1 
II-1 
2 
II-1 
3 
II-1 
4 
II-1 13 
4 
II-2 
5* 
II-3 9 
CTC1 mutation p.Leu247Pro 
p.Gly278Val 
p.Lys242L
eufs*41 
p.Cys985d
el 
p.Leu464Valfs*
66 
p.Arg987Trp 
p.Cys424Gly 
p.Arg987Trp 
p.Cys424Gly 
p.Arg987Trp 
p.Gln241* 
p.Arg975Gly 
Gender F M M M M M 
Age at 
presentation 
6 yrs 7 yrs 15 yrs 9 mo 12 mo 14 yrs 
Current age 
(age at death) 
(22 yrs) 12 yrs (26 yrs) 29 yrs 25 yrs 24 yrs 
In DCR yes yes no no no yes 
Feature       
Abnormal skin 
pigmentation 
+ + +/- - - + 
Nail dystrophy - + - +/- +/- + 
Oral 
leukoplakia 
- - - - - - 
Bone marrow 
failure 
(age at 1st 
report) 
Pancytopenia
/ NSAA 
(12yrs) 
Leucopeni
a/ NSAA 
(8yrs) 
Pancytopenia/ 
NSAA (13yrs) 
- Pancytopenia
/ NSAA 
(12yrs) 
Pancytopenia
/ NSAA 
(14yrs) 
Retinal 
abnormalities 
- - + + + + 
Intracranial 
cysts or 
+ - + + + - 
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calcifications 
Microcephaly + - - - - - 
Developmental 
delay 
+ - - - - + 
Ataxia + - - + + - 
Intrauterine 
growth 
retardation 
+ - - + + + 
Sparse hair + - - - - - 
Premature 
greying 
+ - + + + - 
Skeletal 
abnormalities 
- - + + + + 
Gastrointestin
al 
abnormalities 
- - + - - - 
 
+ = feature present; - = feature absent; +/- = some suggestion; F1-F5 = families 1 to 5; mo = months; yrs = years; * = 
Family previously reported with CTC1 mutations; DCR = Dyskeratosis Congenita Registry, patients within the DCR 
have sufficient features to be classified as DC; NSAA = non severe aplastic anemia. 
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Figure Legends 
 
Figure 1. Segregation and relative position of mutations in CTC1 in patients with DC 
and associated phenotypes. A) Pedigrees associated with CTC1 mutations. Filled 
symbols indicate affected individuals. Identified mutations at the protein level are 
shown below each genotyped individual. “WT” denotes wild type with no mutation. B) 
Schematic structure of CTC1 protein showing the relative location of all reported 
mutations. The black boxes show the predicted oligosaccharide-binding (OB)- folds; 
the N-terminal 700aa region has been shown to be involved in DNA binding where 
as the C-terminal region is involved in STN1 binding. (Number) indicates the number 
of families in which each mutation has been observed. Red identifies novel 
mutations identified in this study. Blue identifies mutations seen in this study and 
previously reported and black identifies mutations seen in other reports. 
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Figure 2. Telomere lengths are not significantly short in our patients with CTC1 
mutations as measured by two different methods. A) Telomere lengths measured by 
MMqPCR expressed as a T/S ratio in bone marrow failure affected patients, 
heterozygous parents with CTC1 mutations and control individuals. There was no 
significant difference when either of the sample groups was compared with controls, 
either as the whole control set or when segregated out to match according to age. 
Black squares = patients with biallelic CTC1 mutations; black triangles = 
heterozygous parents of patients with CTC1 mutations; open diamonds = controls; 
black circles = patients with TERC mutations. B) Telomere length measured by 
Southern blotting Genomic DNA was digested with BamH1 and analysed by 
Southern blot using a 0.75% agarose gel and the subtelomeric probe pTelBam8. [*] 
Telomere lengths were measured as the size of the fragment of peak signal intensity 
and adjusted to exclude the 7.8Kb of subtelomeric DNA. Sizes were determined with 
reference to the same standards run on each gel using Image Quant software. In 
both graphs patients with known mutations in TERC are included as examples of 
short telomeres. Black square = patient F2: II-1; black star = patient F3: II-1; open 
diamonds = controls; black circles = patients with TERC mutations. 
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